论文部分内容阅读
资料表明,多数卵巢癌患者血清免疫抑制酸性蛋白(IAP)升高。鉴于目前最有实用价值的卵巢癌标记物CA125在病变早期敏感性较低,研究探讨了同时测定IAP与CA125在卵巢癌早期诊断的临床意义。材料与方法:健康绝经后妇女66例,经组织学确诊的良性卵巢瘤患者20例,卵巢癌98例(浆液性囊腺癌61例,粘液性囊腺癌7例,子宫内膜样癌14例,未分化癌10例,其他6例)。按FIGO分类,Ⅰ期20例,Ⅱ期12例,Ⅲ期45例,Ⅳ期21例。术前取血,分离血清于-20℃保
Data show that most patients with ovarian cancer serum immunosuppressive acid protein (IAP) increased. In view of the most useful value of ovarian cancer marker CA125 in the early lesion sensitivity is low, the study discussed the simultaneous determination of IAP and CA125 in the early diagnosis of ovarian cancer clinical significance. MATERIALS AND METHODS: Sixty-six healthy post-menopausal women, 20 histologically confirmed benign ovarian tumors, 98 ovarian cancers (serous cystadenocarcinoma 61, mucinous cystadenocarcinoma 7, endometrioid carcinoma 14 Cases, undifferentiated carcinoma in 10 cases, the other 6 cases). According to FIGO classification, stage Ⅰ in 20 cases, stage Ⅱ in 12 cases, stage Ⅲ in 45 cases and stage Ⅳ in 21 cases. Preoperative blood, serum was isolated at -20 ℃